Learn
Celebrating Decades of Trust with ellura®
For more than 20 years, ellura has supported women in maintaining urinary tract health. This translates into consistent urinary tract comfort throughout daily life recommended by urologists and trusted by women around the world.


What Causes UTIs?
UTIs occur when bacteria enter the urinary tract, attach, and multiply, which can lead to common UTI symptoms such as pain or burning during urination, frequent urges, and bladder pressure(15). Understanding how UTIs start can help you better support your urinary tract health.
These are some of the most common reasons UTIs develop:
- Presence of E. coli bacteria(15)
- Bacterial transfer associated with sexual activity(15,1,2)
- Hormonal changes during menopause or pregnancy(15)
- Use of spermicides, diaphragms, or cervical caps(15)
- Frequently delaying urination(15)
- Weakened immune system(15)
- A weakened immune system(11,16, 2)
- Catheter use or certain urinary tract conditions(11,16, 2)
ellura provides clinically backed urinary tract support with its 36 mg of soluble, bioactive A-type PACs. It is designed to help maintain urinary tract function as part of your daily routine, and trusted by healthcare providers and women around the world.
The Science Behind ellura
ellura is the result of over 20 years of scientific research, setting the highest standard in urinary tract support*. Backed by 17 clinical and scientific studies and supported by international herbal-medicine approvals in 22 countries**, ellura delivers 36 mg of soluble, bioactive A-type PACs, clinically backed for their role in supporting urinary tract function*.

Advanced Support Starts with ellura
You’re one step away from elevating your urinary tract care. Each ellura capsule delivers 36 mg of soluble, bioactive A-type PACs to help maintain healthy urinary tract function* day after day. Shop ellura and discover what sets ellura apart.

- Xiong Z, Gao Y, Yuan C, Jian Z, Wei X. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr. 2024 Nov 28;11:1422121.
- Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. (2023). Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD001321.
- Howell, A. B., Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, Tenke P, Sotto A, Lavigne JP. (2010). Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: A multicentric randomized double blind study. BMC Infectious Diseases, 10, 94.
- Lavigne, J. P., Bourg, G., Combescure, C., et al. (2008). In vitro and in vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clinical Microbiology and Infection, 14(4), 350–355.
- World Health Organization -Antibiotic resistance 21 November 2023: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (website)
- Howell, A. B., Dreyfus, J. F., & Chughtai, B. (2022). Differences in urinary bacterial anti-adhesion activity after intake of cranberry dietary supplements with soluble versus insoluble proanthocyanidins. Journal of Dietary Supplements, 19(5), 621–639.
- Chughtai, B., Thomas, D., & Howell, A. (2016). Variability of commercial cranberry dietary supplements for the prevention of uropathogenic bacterial adhesion. American Journal of Obstetrics & Gynecology, 215(1), 122–123.
- Cranberry Fruit Juice Dry Extract. (2023). United States Pharmacopeia-National Formulary (USP-NF).
- Sintara, M., Li, L., Cunningham, D. G., Prior, R. L., Wu, X., & Chang, T. (2018). Single-laboratory validation for determination of total soluble proanthocyanidins in cranberry using 4-dimethylaminocinnamaldehyde. Journal of AOAC International, 101(3), 805–809.
- Uberos, J., et al. (2012). Cranberry syrup vs trimethoprim in the prophylaxis of recurrent urinary tract infections among children: A controlled trial. Open Access Journal of Clinical Trials, 4, 31–38.
- Botto, H., & Neuzillet, Y. (2010). Effectiveness of a cranberry (Vaccinium macrocarpon) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty. Scandinavian Journal of Urology and Nephrology, 44(3), 165–168.
- Bosley, S., Krueger, C. G., Birmingham, A., Howell, A. B., & Reed, J. D. (2024). Improved in vitro hemagglutination assays utilizing P-type and type 1 uropathogenic Escherichia coli to evaluate bacterial anti-adhesion activity of cranberry products. Journal of Dietary Supplements, 21(3), 327–343.
- Anger, J. T., Bixler, B. R., Holmes, R. S., Lee, U. J., Santiago-Lastra, Y., & Selph, S. S. (2022). Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. The Journal of Urology.
- Upton, R., & Brendler, T. (2016). Cranberry fruit Vaccinium macrocarpon Aiton - Standards of analysis, quality control, and therapeutics. American Herbal Pharmacopoeia and Therapeutic Compendium.
- Storme, O., Tirán Saucedo, J., Garcia-Mora, A., Dehesa-Dávila, M., & Naber, K. G. (2019). Risk factors and predisposing conditions for urinary tract infection. Therapeutic Advances in Urology, 11, 1756287218814382.
- Thomas, D., et al. (2017). Does cranberry have a role in catheter-associated urinary tract infections? Canadian Urological Association Journal, 11(11), E421–E424.
- Howell, A. B., Vorsa, N., Der Marderosian, A., & Foo, L. Y. (1998). Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. The New England Journal of Medicine, 339(15), 1085–1086.

